The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer

Saad Atiq; Nathan Hirshman; Afreen Shariff; Tian Zhang

doi:10.1016/j.urolonc.2021.10.002

The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer

Saad Atiq, Nathan Hirshman, Afreen Shariff, Tian Zhang

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have diversified treatments and improved responses and survival for chemotherapy refractory disease. These systemic treatments have associated toxicities which need appropriate management for patients to stay on treatment and potentially have longer benefit from treatment. We review the expected toxicities of immune checkpoint inhibitors, FGFR inhibitors such as erdafitinib, and antibody drug conjugates such as enfortumab vedotin and sacituzumab govitecan.

Original language	English (US)
Pages (from-to)	410-419
Number of pages	10
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	41
Issue number	10
DOIs	https://doi.org/10.1016/j.urolonc.2021.10.002
State	Published - Oct 2023

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.urolonc.2021.10.002

Cite this

@article{0f8248bcfe1a4c5dad154c0d91caf8eb,

title = "The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer",

abstract = "Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have diversified treatments and improved responses and survival for chemotherapy refractory disease. These systemic treatments have associated toxicities which need appropriate management for patients to stay on treatment and potentially have longer benefit from treatment. We review the expected toxicities of immune checkpoint inhibitors, FGFR inhibitors such as erdafitinib, and antibody drug conjugates such as enfortumab vedotin and sacituzumab govitecan.",

author = "Saad Atiq and Nathan Hirshman and Afreen Shariff and Tian Zhang",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2023",

month = oct,

doi = "10.1016/j.urolonc.2021.10.002",

language = "English (US)",

volume = "41",

pages = "410--419",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer

AU - Atiq, Saad

AU - Hirshman, Nathan

AU - Shariff, Afreen

AU - Zhang, Tian

PY - 2023/10

Y1 - 2023/10

N2 - Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have diversified treatments and improved responses and survival for chemotherapy refractory disease. These systemic treatments have associated toxicities which need appropriate management for patients to stay on treatment and potentially have longer benefit from treatment. We review the expected toxicities of immune checkpoint inhibitors, FGFR inhibitors such as erdafitinib, and antibody drug conjugates such as enfortumab vedotin and sacituzumab govitecan.

AB - Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have diversified treatments and improved responses and survival for chemotherapy refractory disease. These systemic treatments have associated toxicities which need appropriate management for patients to stay on treatment and potentially have longer benefit from treatment. We review the expected toxicities of immune checkpoint inhibitors, FGFR inhibitors such as erdafitinib, and antibody drug conjugates such as enfortumab vedotin and sacituzumab govitecan.

UR - http://www.scopus.com/inward/record.url?scp=85121984372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121984372&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2021.10.002

DO - 10.1016/j.urolonc.2021.10.002

M3 - Review article

C2 - 34973855

AN - SCOPUS:85121984372

SN - 1078-1439

VL - 41

SP - 410

EP - 419

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 10

ER -

The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this